BACKGROUND: Our objective was to evaluate liver transplantation as a treatment option for Klatskin tumor. Results for transplanted patients suffering from hilar cholangiocarcinoma were therefore compared to patients after hemihepatectomy. METHODOLOGY: In a retrospective case-control study, seven patients transplanted for hilar cholangiocarcinoma were matched in terms of UICC stage with seven patients who underwent resection of the hilar bifurcation combined with a hemihepatectomy. RESULTS: Median survival was 22 months (range 1-55 months) for patients after liver resection and 64 months (range 1-138 months) for patients after liver transplantation. One and three year overall survival was 71% and 43% after liver resection versus 71% and 57% after liver transplantation. One patient from each group died within one month after surgery. Fatal cerebral bleeding and post-resection liver failure leading to multi-organ failure and sepsis were the causes of early mortality. Three patients are currently alive: one with 64 months after transplantation and two patients with 42 and 55 months after liver resection. CONCLUSIONS: Based on our findings and recently published promising results using liver transplantation for Klatskin tumor, it seems worthwhile to reconsider its potential use in the light of multimodal tumor treatment.
BACKGROUND: Our objective was to evaluate liver transplantation as a treatment option for Klatskin tumor. Results for transplanted patients suffering from hilar cholangiocarcinoma were therefore compared to patients after hemihepatectomy. METHODOLOGY: In a retrospective case-control study, seven patients transplanted for hilar cholangiocarcinoma were matched in terms of UICC stage with seven patients who underwent resection of the hilar bifurcation combined with a hemihepatectomy. RESULTS: Median survival was 22 months (range 1-55 months) for patients after liver resection and 64 months (range 1-138 months) for patients after liver transplantation. One and three year overall survival was 71% and 43% after liver resection versus 71% and 57% after liver transplantation. One patient from each group died within one month after surgery. Fatal cerebral bleeding and post-resection liver failure leading to multi-organ failure and sepsis were the causes of early mortality. Three patients are currently alive: one with 64 months after transplantation and two patients with 42 and 55 months after liver resection. CONCLUSIONS: Based on our findings and recently published promising results using liver transplantation for Klatskin tumor, it seems worthwhile to reconsider its potential use in the light of multimodal tumor treatment.
Authors: B Juntermanns; C D Fingas; G C Sotiropoulos; D Jaradat; A Dechêne; H Reis; S Kasper; A Paul; G M Kaiser Journal: Chirurg Date: 2016-06 Impact factor: 0.955
Authors: Matthias Heuer; Nici M Dreger; Vito R Cicinnati; Christian Fingas; Benjamin Juntermanns; Andreas Paul; Gernot M Kaiser Journal: Eur J Med Res Date: 2012-06-21 Impact factor: 2.175
Authors: Benjamin Juntermanns; Georgios Charalambos Sotiropoulos; Sonia Radunz; Henning Reis; Matthias Heuer; Hideo Andreas Baba; Ali Canbay; Martin Schuler; Guido Gerken; Andreas Paul; Gernot Maximilian Kaiser Journal: Ann Surg Oncol Date: 2012-07-18 Impact factor: 5.344
Authors: Dimitrios Moris; Ioannis D Kostakis; Nikolaos Machairas; Anastasia Prodromidou; Diamantis I Tsilimigras; Kadiyala V Ravindra; Debra L Sudan; Stuart J Knechtle; Andrew S Barbas Journal: PLoS One Date: 2019-07-31 Impact factor: 3.240